These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19109316)

  • 1. Very low prevalence of anti-CCP antibodies in rheumatoid factor-negative psoriatic polyarthritis.
    Pasquetti P; Morozzi G; Galeazzi M
    Rheumatology (Oxford); 2009 Mar; 48(3):315-6. PubMed ID: 19109316
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis.
    Shibata S; Tada Y; Komine M; Hattori N; Osame S; Kanda N; Watanabe S; Saeki H; Tamaki K
    J Dermatol Sci; 2009 Jan; 53(1):34-9. PubMed ID: 18752933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis.
    Vander Cruyssen B; Hoffman IE; Zmierczak H; Van den Berghe M; Kruithof E; De Rycke L; Mielants H; Veys EM; Baeten D; De Keyser F
    Ann Rheum Dis; 2005 Aug; 64(8):1145-9. PubMed ID: 15695535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
    Aridoğan BC; Kaya S; Savaş S; Cetin ES; Akkuş S; Demirci M
    Mikrobiyol Bul; 2008 Oct; 42(4):669-74. PubMed ID: 19149089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheumatoid factor and anti-CCP autoantibodies in rheumatoid arthritis: a review.
    Lee AN; Beck CE; Hall M
    Clin Lab Sci; 2008; 21(1):15-8. PubMed ID: 18335856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.
    Lim MK; Sheen DH; Lee YJ; Mun YR; Park M; Shim SC
    J Rheumatol; 2009 Apr; 36(4):712-6. PubMed ID: 19286846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of the subset of Sjogren's syndrome with articular manifestations by anticyclic citrullinated peptide antibodies.
    Iwamoto N; Kawakami A; Tamai M; Fujikawa K; Arima K; Aramaki T; Kawashiri S; Ichinose K; Kamachi M; Nakamura H; Origuchi T; Ida H; Eguchi K
    J Rheumatol; 2009 Jan; 36(1):113-5. PubMed ID: 19132785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus.
    Hoffman IE; Peene I; Cebecauer L; Isenberg D; Huizinga TW; Union A; Meheus L; De Bosschere K; Hulstaert F; Veys EM; De Keyser F
    Ann Rheum Dis; 2005 Feb; 64(2):330-2. PubMed ID: 15647444
    [No Abstract]   [Full Text] [Related]  

  • 10. IgM-rheumatoid factor and anti-cyclic citrullinated peptide decrease by 50% during intensive treatment in early rheumatoid arthritis.
    van Tuyl LH; Lems WF; Kerstens PJ; Voskuyl AE; Dijkmans BA; Boers M
    Ann Rheum Dis; 2009 Oct; 68(10):1652-3. PubMed ID: 19748920
    [No Abstract]   [Full Text] [Related]  

  • 11. The detecting and clinical value of anti-cyclic citrullinated peptide antibodies in patients with systemic lupus erythematosus.
    Qing YF; Zhang QB; Zhou JG; Yuan GH; Wei J; Xing Y; Liu JP; Jiang L; Chen JP
    Lupus; 2009 Jul; 18(8):713-7. PubMed ID: 19502267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Likelihood ratios as a function of antibody concentration for anti-cyclic citrullinated peptide antibodies and rheumatoid factor.
    Bossuyt X; Coenen D; Fieuws S; Verschueren P; Westhovens R; Blanckaert N
    Ann Rheum Dis; 2009 Feb; 68(2):287-9. PubMed ID: 19139208
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-cyclic citrullinated peptide antibodies in patients affected by HCV-related arthritis.
    Riccio A; Postiglione L; La Dogana P; Spanò A; Marzocchella C; Tarantino G
    J Biol Regul Homeost Agents; 2008; 22(1):57-61. PubMed ID: 18394318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prediction rule for disease outcome in patients with undifferentiated arthritis using magnetic resonance imaging of the wrists and finger joints and serologic autoantibodies.
    Tamai M; Kawakami A; Uetani M; Takao S; Arima K; Iwamoto N; Fujikawa K; Aramaki T; Kawashiri SY; Ichinose K; Kamachi M; Nakamura H; Origuchi T; Ida H; Aoyagi K; Eguchi K
    Arthritis Rheum; 2009 Jun; 61(6):772-8. PubMed ID: 19479686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-cyclic citrullinated peptide antibodies (CCP2) in patients with psoriatic arthritis.
    Ouédraogo DD; Palazzo E; Nicaise-Roland P; Somogyi N; Grootenboer-Mignot S; Hayem G; Meyer O
    Clin Exp Rheumatol; 2007; 25(6):930-1. PubMed ID: 18173933
    [No Abstract]   [Full Text] [Related]  

  • 16. Antibodies to cyclic citrullinated peptides in psoriatic arthritis: do classification criteria affect study results?
    Marchesoni A; Lurati A; Desiati F; Rossi V; Battafarano N
    J Rheumatol; 2006 Feb; 33(2):435; author reply 436-7. PubMed ID: 16465678
    [No Abstract]   [Full Text] [Related]  

  • 17. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis.
    López-Longo FJ; Oliver-Miñarro D; de la Torre I; González-Díaz de Rábago E; Sánchez-Ramón S; Rodríguez-Mahou M; Paravisini A; Monteagudo I; González CM; García-Castro M; Casas MD; Carreño L
    Arthritis Rheum; 2009 Apr; 61(4):419-24. PubMed ID: 19333979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classification criteria for rheumatoid arthritis--time to abandon rheumatoid factor?
    Symmons DP
    Rheumatology (Oxford); 2007 May; 46(5):725-6. PubMed ID: 17215261
    [No Abstract]   [Full Text] [Related]  

  • 19. Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis.
    Rojas-Villarraga A; Diaz FJ; Calvo-Páramo E; Salazar JC; Iglesias-Gamarra A; Mantilla RD; Anaya JM
    J Autoimmun; 2009 Feb; 32(1):64-9. PubMed ID: 19117726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of second- and third-generation assays of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis.
    Kitahara K; Takagi K; Kusunoki Y; Nishio S; Nozaki T; Inomata H; Takei M; Sawada S; Kawai S
    Ann Rheum Dis; 2008 Jul; 67(7):1059-60. PubMed ID: 18556455
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.